Monitoring the safety of COVID-19 vaccination in pregnancy in the UK: A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems.
Jonathan L Richardson, Sally Stephens, Lucy C Chappell, Helen Campbell, Gayatri Amirthalingam, Shennae O'Boyle, Antoaneta Bukasa, Marian Knight, Kenneth K Hodson
{"title":"Monitoring the safety of COVID-19 vaccination in pregnancy in the UK: A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems.","authors":"Jonathan L Richardson, Sally Stephens, Lucy C Chappell, Helen Campbell, Gayatri Amirthalingam, Shennae O'Boyle, Antoaneta Bukasa, Marian Knight, Kenneth K Hodson","doi":"10.1177/1753495X221076713","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.</p><p><strong>Methods: </strong>Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15<sup>th</sup> June 2021.</p><p><strong>Results: </strong>There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (<i>n</i> = 493) and VIP (<i>n</i> = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (<i>n</i> = 501, 55.2%), most women were vaccinated in their second or third trimester (<i>n</i> = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (<i>n</i> = 577, 63.5%).</p><p><strong>Conclusion: </strong>Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.</p>","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":"16 1","pages":"40-47"},"PeriodicalIF":0.8000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126751/pdf/10.1177_1753495X221076713.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X221076713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.
Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021.
Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%).
Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
